Iovance Biotherapeutics, Inc. (FRA:2LB)

Germany · Delayed Price · Currency is EUR

2.438

+0.061 (2.57%)

Last updated: Feb 23, 2026, 8:02 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Innovating, Developing and Commercializing Therapies Using Autologous TIL	164.07M	1.19M	-	-	-
Innovating, Developing and Commercializing Therapies Using Autologous TIL Growth	13698.99%	-	-	-	-
Total	164.07M	1.19M	-	-	-
Total Growth	13698.99%	-	-	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	164.07M	1.19M	-	-	-
United States Growth	13698.99%	-	-	-	-
Total	164.07M	1.19M	-	-	-
Total Growth	13698.99%	-	-	-	-

Source: S&P Global Market Intelligence.